Tag: Transgene

August 1, 2017 Off

Transgene testing Opdivo with Pexa-Vec to treat HCC – first patient treated

By Dino Mustafić

Transgene has treated the first patient in a Phase 1/2 clinical trial for the combination of Pexa-Vec with Opdivo as a first-line treatment of advanced hepatocellular carcinoma (HCC). The trial will assess the safety and tolerability as well as the anti-tumor activity and efficacy of this immunotherapy combination regimen in up to 36 patients (NCT03071094).  This tumour accounts for approximately 75% of liver cancers. 

April 25, 2017 Off

Bristol-Myers and Transgene testing combination of their cancer drugs

By Dino Mustafić

Bristol-Myers Squibb and Transgene have entered a new clinical research collaboration to evaluate the safety, tolerability and efficacy of Transgene’s investigational therapeutic vaccine TG4010 in combination with Bristol-Myers Squibb’s Opdivo (nivolumab) + standard chemotherapy (CT) as a first-line treatment for advanced non-squamous non-small cell lung cancer (NSCLC) in patients whose tumors have low or undetectable levels of PD-L1.